Is there a need for axillary dissection in breast cancer?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 2, 2011, Pages 225-230

  Wilson, Jason P ^a   Mattson, David ^b   Edge, Stephen B ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Axillary node dissection; Breast cancer; Radiation

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; HUMAN; LYMPH NODE DISSECTION; MICROMETASTASIS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE; TUMOR CELL;

EID: 79951518795     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0017     Document Type: Article

References (39)

1. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-575.
2. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002:347:1227-1232. (Pubitemid 35176241)
3. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-398.
4. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-7720. (Pubitemid 46291835)
5. Kim HJ, Son BH, Lim WS, et al. Impact of omission of axillary lymph node dissection after negative sentinel lymph node biopsy: 70-month follow-up. Ann Surg Oncol 2010;17:2126-2131.
6. Bafford A, Gadd M, Gu X, et al. Diminishing morbidity with the increased use of sentinel node biopsy in breast carcinoma. Am J Surg 2010;200:374-377.
7. Wasif N, Ye X, Giuliano AE. Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty. Ann Surg Oncol 2009;16:2442-2449.
8. Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol 2009;16:687-696.
9. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946-2953.
10. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983;52:1551-1557. (Pubitemid 13018271)
11. Peare R, Staff RT, Heys SD. The use of FDG-PET in assessing axillary lymph node status in breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2010;123:281-290
12. Javid S, Segara D, Lofti P, et al. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy? Ann Surg Oncol 2010;17:1841-1846.
13. Edge SB, Byrd DR, Compton CC, et al. AJCC Staging Manual, 7th ed. New York, NY: Springer; 2010.
14. Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:44-46.
15. Fisher ER, Palekar A, Rockette H, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). V. Significance of axillary nodal micro- and macrometastases. Cancer 1978;42:2032-2038.
16. Hansen NM, Grube B, Ye X, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol 2009;27:4679-4684.
17. De Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009;361:653-663.
18. Krag DN, Julian TB, Harlow SP, et al. NSABP-32: phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: a description of the trial. Ann Surg Oncol 2004;11(Suppl 3):208S-210S.
19. Krag DN, Anderson SJ, Julian TB, et al. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract LBA505.
20. Cote RJ, Giuliano A, Hawes D, et al. ACOSOG Z0010: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer [abstract]. Presented at ASCO Annual Meeting; June 4-8, 2010; Chicago, Illinois. Abstract CRA504.
21. Carlson, RW, Allred DC, Anderson BO, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2, 2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed August 9, 2010.
22. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003;10:1140-1151. (Pubitemid 40486808)
23. Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg 2009;208:229-235.
24. Specht MC, Kattan MW, Gonen M, et al. Predicting nonsentinel node status after positive sentinel lymph node biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol 2005;12:654-659. (Pubitemid 41126095)
25. Barranger E, Coutant C, Flahault A, et al. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 2005;91:113-119. (Pubitemid 40684923)
26. Pugliese MS, Karam AK, Hsu M, et al. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer. Ann Surg Oncol 2010;17:1063-1068.
27. Tjan-Heijnen VC, Pepels MJ, de Boer M, et al. Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (axRT) in breast cancer patients with micrometastases (PN1mi) or isolated tumor cells (pN0[1+]) in the sentinel lymph node (SN): results from the MIRROR study [abstract]. Presented at the 2009 ASCO Annual Meeting; May 30-June 2, 2009; Orlando, Florida. Abstract CRA506.
28. Straver ME, Meljnen P, van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010;28:731-737.
29. Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 1894;20:497-555.
30. Fisher B, Redmond C, Fisher ER. The contribution of recent NSABP clinical trial of primary breast cancer therapy to an understanding of tumor biology - an overview of findings. Cancer 1980;46(Suppl 4):1009-1025. (Pubitemid 10027061)
31. Giuliano A, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426-433.
32. Hoebers FJ, Borger JH, Hart AA, et al. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with carcinoma and clinically negative axillary lymph nodes. Cancer 200;88:1633-1642.
33. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;17:2087-2106. (Pubitemid 41797643)
34. Veronesi U, Orecchia R, Zurrida S, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol 2005;16:383-388. (Pubitemid 40458313)
35. Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004;22:97-101. (Pubitemid 41095119)
36. Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol 2010;28:3929-3936.
37. Norman SA, Localio AR, Kallan MJ, et al. Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 2010;19:2734-2746.
38. Askikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010;102:111-118.
39. Goldberg JI, Wiechmann LI, Riedel ER, et al. Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema. Ann Surg Oncol 2010;17:3278-3286.